Replies to post #706046 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

FeMike,

Exactly! The issue is that any offer actually draws attention to NWBO and big pharma can’t take the chance that people will actually figure out what NWBO has. That would turn their products into second and third rate treatments that might not even be useful in the treatment of disease while still being debilitating. They are making too much money where they are at and want that money coming in all the way through patent expiration.
The issue with an offer is Linda can shoot it down with the control she has and then you have a situation where NWBO gets publicity without big pharma getting what they want. Nope, bonifide offers will only come when individual situations dictate there is no other choice. Can’t wait for Flaskworks. Best wishes.

[skitahoe]

A company need not get an offer to have a discussion. If for instance Merck was interested and asked LP what it would take for you to be interested in selling the company she could answer XXX billion. They could even agree to get together again when the share price gave NWBO a market cap approaching half of XXX billions. It's not an offer, just an agreement to talk again when the time is right. I'd not be surprised if such discussions have occurred.

Likewise, I'd not be surprised at all if CRL and NWBO have reached agreements on CRL being their CDMO for certain parts of the world, but the agreement isn't triggered until certain events occur. One of those events might be the EDEN approval for commercial production in certain countries. Another might be the submission and acceptance of documents requesting approval in certain countries. I'm not saying this is the case, I'm saying I'd not be surprised if it was.

Gary

[learningcurve2020]

If LP ever received an offer greater than the current market cap the word would be out on the Street. It'd be obscene to raise cash at these dreadful prices knowing she had a 2X or 3X current share price offer. No way.